SFM
SCLN

Systematic Financial Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Systematic Financial Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-134,442
Closed -$1.32M – 726
2017
Q1 		$1.32M Sell
134,442
-32,365
-19% -$323K 0.02% 563
2016
Q4 		$1.8M Buy
166,807
+7,180
+4% +$71.8K 0.03% 411
2016
Q3 		$1.64M Buy
159,627
+19,750
+14% +$215K 0.02% 473
2016
Q2 		$1.83M Sell
139,877
-4,315
-3% -$56.5K 0.02% 373
2016
Q1 		$1.59M Sell
144,192
-20,840
-13% -$185K 0.02% 457
2015
Q4 		$1.52M Sell
165,032
-108,640
-40% -$909K 0.02% 502
2015
Q3 		$1.9M Sell
273,672
-6,385
-2% -$54.7K 0.02% 520
2015
Q2 		$2.75M Sell
280,057
-7,343
-3% -$66.9K 0.02% 365
2015
Q1 		$2.55M Buy
287,400
+23,375
+9% +$186K 0.02% 444
2014
Q4 		$2.31M Buy
+264,025
New +$2.14M 0.02% 464

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Systematic Financial Management's SCLN Position: Q2 2017 in Review

Systematic Financial Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 134,442 shares — an estimated $1.32M sold.

Systematic Financial Management first reported a position in SCLN in Q4 2014 and held it in 10 quarters. The position peaked at $2.75M in Q2 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Systematic Financial Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Systematic Financial Management sold 134,442 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $1.32M.
  • Systematic Financial Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 10 quarters.
  • Systematic Financial Management's Sciclone Pharmaceuticals Inc position peaked at $2.75M in Q2 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Systematic Financial Management's 13F filing for Q2 2017, filed 10 Aug 2017.